drugset / Trial / NCT01328925

Efficacy Study of Nitazoxanide Suspension in the Treatment of Rotavirus Disease in Children

NCT01328925

Phase 2 Completed 100 enrolled Romark Laboratories L.C.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the effectiveness of nitazoxanide suspension compared to placebo in treating rotavirus disease in pediatric patients less than 6 years of age.

Timeline

Start
2005-12
Primary completion
2006-06
Completion
2006-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Nitazoxanide Other / unclassified 7.5 mg/kg Oral
Subject Nitazoxanide Other / unclassified 100 mg Oral
Subject Nitazoxanide Other / unclassified 200 mg Oral

Indications